ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "rheumatoid arthritis"

  • Abstract Number: 1890 • ACR Convergence 2024

    Emergency Department Visits for Ambulatory Care Sensitive Conditions by Persons with Rheumatoid Arthritis: A Population-Based Study

    Dani Contreras1, Zanir Bhanji1, J. Antonio Avina-Zubieta2, Claire Barber1 and Cheryl Barnabe1, 1University of Calgary, Calgary, AB, Canada, 2Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Ambulatory Care Sensitive Conditions (ACSCs) are conditions where appropriate access to ambulatory care could prevent or reduce complications, a more severe disease course, or…
  • Abstract Number: 1978.5 • ACR Convergence 2024

    Post-Hoc Analysis of Clinically Relevant Anti-Vaccine Antibodies in Participants with Rheumatoid Arthritis Treated with Nipocalimab

    Faye Yu1, Eugene Myshkin2, Carolina Bobadilla Mendez3, Marta Cossu4, Kaiyin Fei5, Qingmin Wang6, Matthew J. Loza6, Dessislava Dimitrova3 and Sheng Gao3, 1Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, USA, MA, MA, 2Janssen Research & Development, LLC, a Johnson & Johnson company, Cambridge, MA, 3Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, 4Janssen Pharmaceutical Research and Development, a Johnson & Johnson company, Leiden, Netherlands, 5Janssen Research & Development, LLC, Spring House, PA, 6Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, USA, Spring House, PA

    Background/Purpose: Nipocalimab is a fully human, high affinity, aglycosylated, effectorless IgG1 monoclonal antibody designed to selectively block neonatal fragment crystallizable receptor (FcRn), thereby lowering IgG…
  • Abstract Number: 2211 • ACR Convergence 2024

    Identifying Clinical Predictors of Difficult-to-Treat Rheumatoid Arthritis Using Machine Learning-based Techniques

    Jiri Baloun1, Lucie Andrés Cerezo2, Tereza Kropáčková3, Aneta Prokopcova4, Kristýna Brábníková Marešová1, Herman Mann5, Jiří Vencovský3, Karel Pavelka6 and Ladislav Šenolt3, 1Institute of Rheumatology, Prague, Czech Republic, 2Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 3Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, 4First faculty of medicine and Institute of Rheumatology, Charles University, Prague, Czech Republic, 5Revmatologický ústav, Praha, Czech Republic, 6Institute of Rheumatology and Charles University, Praha, Czech Republic

    Background/Purpose: Despite advances in biologic (b-) and targeted synthetic (ts-) disease-modifying anti-rheumatic drugs (DMARDs), a significant subset of rheumatoid arthritis (RA) patients remain symptomatic, meeting…
  • Abstract Number: 2229 • ACR Convergence 2024

    Aptamer Based Proteomic Profiling Demonstrates Significant Differences in Methotrexate Responders versus Non-responders in Newly Diagnosed Rheumatoid Arthritis and Adds Potential Value to Clinical Examination

    Kaien Gu1, Leanne Lac1, Nathalie Carrier2, Liam O'Neil1, Gilles Boire3, Pingzhou Hu4 and Carol Hitchon1, 1University of Manitoba, Winnipeg, MB, Canada, 2Universite de Sherbrooke, Sherbrooke, QC, Canada, 3Retired, Sherbrooke, QC, Canada, 4Western University, London, ON, Canada

    Background/Purpose: Despite methotrexate (MTX) being the cornerstone of rheumatoid arthritis (RA) therapy, uncertainty exists around who will respond to MTX. We aimed to determine the…
  • Abstract Number: 2245 • ACR Convergence 2024

    Clinical Efficacy and Molecular Cardiovascular Changes of Baricitinib in Biologic-naïve Patients with Rheumatoid Arthritis. Direct Comparative Analysis with TNF Inhibitors and Conventional DMARDs

    Chary Lopez-Pedrera1, Laura Muñoz-Barrera2, Rafaela Ortega-Castro3, Sagrario Corrales2, Jerusalén Calvo4, Concepción Aranda-Valera5, María Lourdes Ladehesa-Pineda1, Pilar Font2, Ismael Sánchez Pareja2, Elena Moreno-Caño5, María Carmen Ábalos-Aguilera6, Christian Merlo-Ruiz6, Mª Angeles Aguirre-Zamorano7, Tomás Cerdó2, Nuria Barbarroja2, Carlos Perez-Sanchez2 and Alejandro Escudero-Contreras2, 1IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Andalucia, Spain, 2IMIBIC/Reina Sofia Hospital/University of Cordoba, Cordoba, Spain, 3Hospital Reina Sofía, Cordoba, Andalucia, Spain, 4IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Spain, 5IMIBIC/Reina Sofia Hospital/University of Cordoba, Córdoba, Andalucia, Spain, 6IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Spain, 7IMIBIC/Reina Sofia Hospital/University of Cordoba, CÓRDOBA, Andalucia, Spain

    Background/Purpose: The main objective of this study was to conduct extensive clinical and molecular analyses to accurately characterize the specific effects of Baricitinib (4 mg/day)…
  • Abstract Number: 2265 • ACR Convergence 2024

    Patient’s Global Assessment of Disease Activity Is the Most Relevant Factor for Near-Miss of Boolean 2.0 Remission in Patients with Rheumatoid Arthritis: Post Hoc Analysis from the Observational UPwArds Study

    Torsten Witte1, Uta Kiltz2, Florian Haas3, Elke Riechers4, Ulrich Prothmann5, Daniela Adolf6, Alexander Rössler7, Kirsten Famulla8, Konrad Götz7 and Klaus Krüger9, 1Dept of Immunology and Rheumatology, Hannover, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University, D-44649 Herne, Germany, 3Internistisch-Rheumatologische Facharztpraxis, Rheumatology, Tübingen, Germany, 4Hannover Medical School, Department for Rheumatology and Immunology, Herne, Germany, 5Knappschaftsklinikum Saar GmbH, Püttlingen, Germany, 6StatConsult GmbH, Statistics, Magdeburg, Germany, 7AbbVie Deutschland GmbH & Co. KG, Immunology, Wiesbaden, Germany, 8AbbVie Deutschland GmbH & Co. KG, Immunology, North Chicago, 9Rheumatologisches Praxiszentrum, Munich, Germany, München, Germany

    Background/Purpose: Patient’s Global Assessment of disease activity (PtGA) was found to be the most relevant limiting factor for achieving Boolean 1.0 remission in patients with…
  • Abstract Number: 2283 • ACR Convergence 2024

    Characterization of Second-Line Therapy After First Janus Kinase Inhibitor Use: Results from the CorEvitas RA Registry

    Joshua Baker1, Kristi Mizelle2, Wassim Saikali3, Page Moore4, Hyung-Joo Kang4, David Gruben5, Ahmed Shelbaya6, Lori Stockert7 and Jacqueline O'Brien4, 1Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, 2TPMG Rheumatology, Newport News, VA, 3Rheumatology and Pulmonary Clinic, Beckley, WV, 4CorEvitas, LLC, Waltham, MA, 5Pfizer Inc, Groton, CT, 6Pfizer Inc, New York, NY, 7Pfizer Inc, Collegeville, PA

    Background/Purpose: Janus kinase inhibitors (JAKi) are a widely acceptable drug class in the treatment of RA. However, real-world data on the patterns of JAKi use and…
  • Abstract Number: 2589 • ACR Convergence 2024

    A Nationwide Analysis of Risk of Acute Coronary Syndrome in RA Patients with Interstitial Lung Disease

    Omair Khan1, Azka Naeem2, Kundan Jana2, Syed Mujtaba Baqir2, Tharun Shyam2 and Saumya Nanda2, 1Maimonides Medical Center, Council Bluffs, IA, 2Maimonides Medical Center, Brooklyn, NY

    Background/Purpose: Rheumatoid Arthritis (RA) and Interstitial Lung Disease (ILD) are systemic inflammatory conditions that independently increase the risk of Acute Coronary Syndrome (ACS). However, there…
  • Abstract Number: 2675 • ACR Convergence 2024

    Which Arthralgia Patients at Risk for RA Benefited from Treatment with Methotrexate?; Results from the TREAT EARLIER Trial

    Stijn Claassen1, Quirine Dumoulin2, Kasper Glas3, Esmeralda Molenaar4, Hanna van Steenbergen1 and Annette van der Helm-van Mil5, 1Leiden University Medical Center, Leiden, Netherlands, 2Leiden University Medical Centre, Leiden, Zuid-Holland, Netherlands, 3Reumazorg Zuid West Nederland, Goes, The Netherlands, Goes, Zeeland, Netherlands, 4Groene Hart Ziekenhuis, Gouda, The Netherlands, Gouda, Zuid-Holland, Netherlands, 5LUMC, Leiden, Zuid-Holland, Netherlands

    Background/Purpose: A one-year methotrexate treatment in CSA has been shown to induce sustained reduction in subclinical inflammation during 2-years follow-up. We aim to study if…
  • Abstract Number: 0012 • ACR Convergence 2024

    Dichotomous Expression of CXCR3 and CCR9 and Relationship to Intestinal Permeability in B Cells in Rheumatoid Arthritis

    Ken Yasaka, Ruoqiao Wang, Nida Pellett, Daria Krenitsky, Juilee Thakar and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY

    Background/Purpose: The gut is a key mucosal tissue that can impact the immune system and contribute to systemic inflammation in the setting of increased intestinal…
  • Abstract Number: 0047 • ACR Convergence 2024

    Asthma Is Associated with Increased Serum IgA Antibodies to Citrullinated Peptide Antigenscompared to Healthy Controlsin Discovery and Validation Cohorts

    Drayton Rorah1, Linh Ngo2 and Scott Matson3, 1University of Kansas, Internal Medicine, Kansas City, KS, 2University of Kansas School of Medicine, Kansas City, 3University of Kansas, Kansas City, MO

    Background/Purpose: The connection between airway inflammation as seen in patients with asthma and rheumatoid arthritis (RA) has been suggested by previous epidemiologic studies. For instance,…
  • Abstract Number: 0065 • ACR Convergence 2024

    Evidence of Membranolytic Targeting and Intracellular Citrullinationin Neutrophils Isolated from Patients with Rheumatoid Arthritis

    Neela Fatemeh Moadab1, Tal Gazitt2, Rayan Najjar1, Ethan Le1, J Lee Nelson3, Vijay Joshua4, Keith Elkon1, Caroline Grönwall4 and Tomas Mustelin1, 1University of Washington, Seattle, WA, 2Carmel Hospital, Haifa, Israel, 3University of Washington and Fred Hutchinson Cancer Center, Seattle, WA, 4Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Anti-citrullinated protein autoantibodies (ACPA) are diagnostic for rheumatoid arthritis (RA). The antigens recognized by these autoantibodies are produced by protein arginine deiminases (PADs), particularly…
  • Abstract Number: 0158 • ACR Convergence 2024

    Rheumatoid Arthritis Testing Patterns by Physicians and Advanced Practice Providers from a National Commercial Laboratory, 2014 – 2023

    Karis Lee1, Min Kyung Lee2, David Alfego3, Kristen Clark4 and Stanley Naides5, 1Labcorp, Orlando, FL, 2Labcorp, San Diego, CA, 3Labcorp, Carlsbad, CA, 4Labcorp, Raleigh, NC, 5Labcorp, Dana Point, CA

    Background/Purpose: With the commercialization of new diagnostic and monitoring tests for rheumatoid arthritis (RA) and an increasing number of advanced practice providers (APPs) in the…
  • Abstract Number: 0259 • ACR Convergence 2024

    Whipple’s Disease in Patients Initially Diagnosed with Rheumatic Diseases: A Case Series

    Judith den Hertog1, Maike Wientjes1, Jaap ten Oever2, Merel Opdam1, Denise Telgt1 and Alfons den Broeder1, 1Sint Maartenskliniek, Ubbergen, Netherlands, 2Radboudumc, Nijmegen, Netherlands

    Background/Purpose: Whipple’s disease is a presumably rare, chronic infectious disease caused by the bacterium Tropheryma whipplei. Symptoms include weight loss, diarrhea, abdominal discomfort, joint pain…
  • Abstract Number: 0432 • ACR Convergence 2024

    Disease Activity During Pregnancy in Patients with Rheumatoid Arthritis or Spondyloarthritis: Results from the Multicentre Prospective GR2 Study

    Marion couderc1, celine lambert2, sabrina hamroun3, denis gallot4, Nathalie Costedoat-chalumeau5, Laure Gossec6, Gaëlle Guettrot-Imbert7, Veronique LE GUERN7, Christophe Richez8, MArtin Soubrier9 and Anna Molto10, 1CHU de Clermont-Ferrand, Clermont-Ferrand, 2chu clermont ferrand, clermont ferrand, France, 3Rheumatology Department - Cochin Hospital, Paris, France, 4Department of Obstetrics, CHU Clermont-ferrand, Clermont-Ferrand, Auvergne, France, 5University Paris Cité, Paris, France, 6Sorbonne Université, Paris, France, 7Cochin Hospital, Paris, France, 8Université de Bordeaux, Bordeaux, France, 9Gabriel-Montpied Hospital, Clermont-ferrand, France, 10Groupe Hospitalier Cochin, AP-HP, Paris, France

    Background/Purpose: Pregnancy may have a beneficial effect on disease activity in rheumatoid arthritis (RA) but the evidence is more conflicting in spondyloarthritis (SpA). The aim…
  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 188
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology